Public Health Partnering Terms and Agreements

Published: August 2014
No. of Pages: 942
   

"Delivery of this report will take 1-3 days after purchase."

The Public Health Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter public health partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest public health deals and contracts announced in the healthcare sectors.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this report provide an orientation of public health dealmaking and business activities. Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in public health dealmaking since 2009 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading public health deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of public health deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all public health deals since 2009 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all public health partnering deals signed and announced since 2009. The chapter is organized by specific public health therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all public health partnering deals signed and announced since 2009. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in public health partnering and dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of public health technologies and products.

Benefits

Public Health Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of public health deal trends since 2009
  • Access public health deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between public health partner companies
  • Comprehensive access to links to actual public health deals entered into by the world’s biopharma companies
  • Indepth review of public health deals entered into by the leading fifty bigpharma companies
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner public health opportunities
  • Uncover companies actively partnering public health opportunities

Report scope

Public Health Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to public health trends and structure of deals entered into by leading companies worldwide.

Public Health Partnering Terms and Agreements includes:

  • Trends in public health dealmaking in the biopharma industry since 2009
  • Analysis of public health deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of public health deal contract documents
  • Comprehensive access to public health deal records
  • The leading public health deals by value since 2009
  • Most active public health dealmakers since 2009

In Public Health Partnering Terms and Agreements, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Public Health Partnering Terms and Agreements

Table of Contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in public health dealmaking
2.1. Introduction
2.2. Public health partnering over the years
2.3. Bigpharma public health dealmaking activity
2.4. Bigpharma not active in public health
2.5. Public health partnering by deal type
2.6. Public health partnering by industry sector
2.7. Public health partnering by stage of development
2.8. Public health partnering by technology type
2.9. Public health partnering by dermatology indication
2.10. Average deal terms for public health
2.10.1 Public health headline values
2.10.2 Public health upfront payments
2.10.3 Public health milestone payments
2.10.4 Public health royalty rates

Chapter 3 – Leading public health deals
3.1. Introduction
3.2. Top public health deals by value
3.3. Top public health deals involving bigpharma

Chapter 4 – Bigpharma public health deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma public health partnering company profiles
Abbott
Actavis
Actelion
Allergan
Amgen
Astellas
AstraZeneca
Baxter International
Bayer
Bristol-Myers
Squibb C
elgene
Eli Lilly
Endo Pharmaceuticals
Forest Laboratories
Galderma
GlaxoSmithKline
Hospira
Johnson & Johnson
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Pfizer
Roche
Sanofi
Shionogi
Shire
Teva
Warner Chilcott
Watson

Chapter 5 – Public health partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
Development
Distribution
Equity purchase
Joint venture
Licensing
Litigation
Loan
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
5.3. By stage of development
Discovery
Formulation
Marketed
Phase I
Phase II
Phase III
Preclinical
5.4. By technology type
Antibodies
Assays
Biologicalcompounds
Biomaterials
Clinical testing
Devices
Diagnostics
DNA probes
Drug delivery
Enabling technology
Equipment
Genomics
Natural product
Oligonucleotide
Orphan drug
Peptides
Processes
Recombinant DNA
Regenerative medicine
Research services
Research supplies
Screening
Small molecules
Stem cells

Chapter 6 – Public health dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Public health
Smoking addiction
Drug addictin
Alcohol addiction
Obesity
Health education
Preventative medicine

Chapter 7 – Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 – Directory of public health deals by company A-Z 2009-2014
Appendix 2 – Directory of public health deals by deal type 2009-2014

Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Contract service
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Loan
Manufacturing
Manufacturing - OEM
Marketing
Material transfer
Option
Promotion
Research
Royalty financing
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 3 - Directory of public health deals by stage of development 2009-2014
Appendix 4 – Directory of public health deals by technology type 2009 - 2014
Appendix 5 – Deal type definitions

About Wildwood Ventures
Current Partnering
Current Agreements
Recent titles from CurrentPartnering
Order Form – Reports

List of Figures

Figure 1: Public health partnering since 2009
Figure 2: Bigpharma – top 50 – public health deals 2009 to 2014
Figure 3: Bigpharma public health deal frequency – 2009 to 2014
Figure 4: Inactive bigpharma in public health 2009-2014
Figure 5: Public health partnering by deal type since 2009
Figure 6: Public health partnering by industry sector since 2009
Figure 7: Public health partnering by stage of development since 2009
Figure 8: Public health partnering by technology type since 2009
Figure 9: Public health partnering by dermatology target since 2009
Figure 10: Public health deals with a headline value
Figure 11: Public health deal headline value distribution, US$million – discovery stage
Figure 12: Public health deal headline value distribution, US$million – preclinical stage
Figure 13: Public health deal headline value distribution, US$million – phase I stage
Figure 14: Public health deal headline value distribution, US$million – phase II stage
Figure 15: Public health deal headline value distribution, US$million – phase III stage
Figure 16: Public health deal headline value distribution, US$million – regulatory stage
Figure 17: Public health deal headline value distribution, US$million – marketed stage
Figure 18: Summary median headline value by stage of development, 2009-2014
Figure 19 Public health deals with upfront payment values
Figure 20: Public health deal upfront payment distribution, US$million – discovery stage
Figure 21: Public health deal upfront payment distribution, US$million – preclinical stage
Figure 22: Public health deal upfront payment distribution, US$million – phase I stage
Figure 23: Public health deal upfront payment distribution, US$million – phase II stage
Figure 24: Public health deal upfront payment distribution, US$million – phase III stage
Figure 25: Public health deal upfront payment distribution, US$million – regulatory stage
Figure 26: Public health deal upfront payment distribution, US$million – marketed stage
Figure 27: Summary median upfront payments by stage of development, 2009-2014
Figure 28: Public health deals with milestone payments
Figure 29: Public health deal milestone distribution, US$million – discovery stage
Figure 30: Public health deal milestone distribution, US$million – preclinical stage
Figure 31: Public health deal milestone distribution, US$million – phase I stage
Figure 32: Public health deal milestone distribution, US$million – phase II stage
Figure 33: Public health deal milestone distribution, US$million – phase III stage
Figure 34: Public health deal milestone distribution, US$million – regulatory stage
Figure 35: Public health deal milestone distribution, US$million – marketed stage 94
Figure 36: Public health deals with royalty rates, %
Figure 37: Public health deal royalty rate distribution, US$million – discovery stage
Figure 38: Public health deal royalty rate distribution, US$million – preclinical stage
Figure 39: Public health deal royalty rate distribution, US$million – phase I stage
Figure 40: Public health deal royalty rate distribution, US$million – phase II stage
Figure 41: Public health deal royalty rate distribution, US$million – phase III stage
Figure 42: Public health deal royalty rate distribution, US$million – regulatory stage
Figure 43: Summary median royalty rate by stage of development, 2009-2014
Figure 44: Top public health deals by value since 2009
Figure 45: Top Public health deals signed by bigpharma value since 2009
Figure 46: Online partnering resources
Figure 47: Forthcoming partnering events

Published By: Current Partnering
Product Code: Current Partnering113


Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and we’ll share relevant market report titles for you to explore.

Related Reports:


Why ReportsnReports.com?

  • 400,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: sales@reportsandreports.com Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Pharmaceuticals market as per your needs. Get the best of Pharmaceuticals research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Email Alerts

Get Email alerts about market research reports from industries and publishers of your interest:

Live Chat
Live Chat by Comm100